Literature DB >> 1388247

Inhibition of histamine turnover by 8-OH-DPAT, buspirone and 5-hydroxytryptophan in the mouse and rat brain.

R Oishi1, Y Itoh, K Saeki.   

Abstract

The effects of 5-hydroxytryptamine (5-HT) receptor agonists on histamine turnover in mouse and rat brains were examined. The histamine turnover rate was estimated from the accumulation of tele-methylhistamine 90 min after i.p. injection of pargyline (65 mg/kg). In whole mouse brains, the histamine turnover was significantly inhibited by the 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (greater than 0.5 mg/kg) and buspirone (greater than 2 mg/kg) injected s.c. 10 min before pargyline treatment. 5-hydroxytryptophan (20 mg/kg) also significantly inhibited histamine turnover. Injections of the 5-HT1B agonist m-trifluoromethylphenylpiperazine (10 and 20 mg/kg) or the 5-HT2 agonist (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (1, 2 and 5 mg/kg), however, did not affect histamine turnover. The inhibitory effect of 8-OH-DPAT (1 mg/kg) on histamine turnover was significantly antagonized (by 40%) by pindolol (20 mg/kg) and slightly antagonized (by 29%) by spiperone (10 mg/kg), while methysergide (20 mg/kg) and ketanserin (10 mg/kg) demonstrated no antagonistic effects. 8-OH-DPAT (0.3 and 1 mg/kg) also showed an inhibiting effect on histamine turnover in various regions of rat brains. Although the extent of inhibition was slightly larger in the striatum and cerebral cortex, there was no marked regional difference. These results suggest that histaminergic activity in the brain is regulated by 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388247     DOI: 10.1007/bf00168939

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

1.  Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis.

Authors:  T Sharp; S R Bramwell; S Hjorth; D G Grahame-Smith
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

2.  delta 9-Tetrahydrocannabinol decreases turnover of brain histamine.

Authors:  R Oishi; Y Itoh; M Nishibori; K Saeki
Journal:  J Pharmacol Exp Ther       Date:  1985-02       Impact factor: 4.030

3.  Alpha 2-adrenoceptor-mediated inhibition of histamine release from rat cerebral cortical slices.

Authors:  S J Hill; R M Straw
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

4.  Effects of isofloxythepin on central and peripheral histamine systems.

Authors:  K Saeki; R Oishi; M Nishibori; Y Itoh
Journal:  Jpn J Pharmacol       Date:  1989-05

5.  Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).

Authors:  J A Engel; S Hjorth; K Svensson; A Carlsson; S Liljequist
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

6.  Feeding-related circadian variation in tele-methylhistamine levels of mouse and rat brains.

Authors:  R Oishi; Y Itoh; M Nishibori; K Saeki
Journal:  J Neurochem       Date:  1987-08       Impact factor: 5.372

7.  Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HT1A receptors negatively coupled with adenylate cyclase in hippocampal neurons.

Authors:  J Bockaert; A Dumuis; R Bouhelal; M Sebben; R N Cory
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

8.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT.

Authors:  H Gozlan; S El Mestikawy; L Pichat; J Glowinski; M Hamon
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

9.  Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists.

Authors:  J S Sprouse; G K Aghajanian
Journal:  Synapse       Date:  1987       Impact factor: 2.562

10.  Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties.

Authors:  M Hamon; C M Fattaccini; J Adrien; M C Gallissot; P Martin; H Gozlan
Journal:  J Pharmacol Exp Ther       Date:  1988-08       Impact factor: 4.030

View more
  6 in total

1.  Inhibition of type 4 cAMP-phosphodiesterases (PDE4s) in mice induces hypothermia via effects on behavioral and central autonomous thermoregulation.

Authors:  Will McDonough; Justin Rich; Ileana V Aragon; Lina Abou Saleh; Abigail Boyd; Aris Richter; Anna Koloteva; Wito Richter
Journal:  Biochem Pharmacol       Date:  2020-07-20       Impact factor: 5.858

2.  Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic.

Authors:  Fumikazu Yokoyama; Miki Yamauchi; Masayo Oyama; Kunihiro Okuma; Kaname Onozawa; Takako Nagayama; Rie Shinei; Makoto Ishikawa; Yasuo Sato; Nobukazu Kakui
Journal:  Psychopharmacology (Berl)       Date:  2009-04-09       Impact factor: 4.530

3.  Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases.

Authors:  C Y Jin; O Anichtchik; P Panula
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 4.  Histaminergic mechanisms for modulation of memory systems.

Authors:  Cristiano André Köhler; Weber Cláudio da Silva; Fernando Benetti; Juliana Sartori Bonini
Journal:  Neural Plast       Date:  2011-08-18       Impact factor: 3.599

5.  Anxiolytic and antidepressant-like activities of the novel and potent non-imidazole histamine H₃ receptor antagonist ST-1283.

Authors:  Amine Bahi; Johannes Stephan Schwed; Miriam Walter; Holger Stark; Bassem Sadek
Journal:  Drug Des Devel Ther       Date:  2014-05-28       Impact factor: 4.162

6.  The histaminergic system is involved in psychological stress-induced hyperthermia in rats.

Authors:  Battuvshin Lkhagvasuren; Takakazu Oka
Journal:  Physiol Rep       Date:  2017-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.